Skip to main content

COVID-19 Updates: Get the latest on vaccine information, in-person appointments, video visits and more. Learn More >>

Clinical Trials and Novel Therapies

Clinical Trials and Novel Therapies

As a recognized leader in clinical and laboratory research, Texas Children’s Cancer and Hematology Center offers clinical trials for a wide range of children’s cancer and blood disorders. The trials we offer are the result of physician scientists pioneering the translation of breakthrough research findings from the laboratory to the clinic.

We have over 350 researchers in 47 laboratories performing cutting-edge research and over 250 active therapeutic clinical trials, many of which are only available at Texas Children’s. We work closely with the pharmaceutical industry to make important new agents available for children with cancer and blood disorders.

Our physicians develop trials and participate in all major pediatric cancer and blood disorder cooperative clinical trial groups, like the Children’s Oncology Group (COG) and the Pediatric Brain Tumor Consortium (PBTC).

Search our featured clinical trials & novel therapies


Featured Immunotherapy Trials and Novel Therapies

Administration of rapidly generated LMP, BARF1 and EBNA1 specific cytotoxic T-lymphocytes to patients with EBV-positive lymphoma

GINAKIT2 - Treatment for neuroblastoma (H-41033)

KYMRIAH®: The first FDA-approved gene therapy for relapsed or refractory B-cell acute lymphoblastic leukemia (ALL)

New immunotherapy for children with hepatoblastoma or hepatocellular carcinoma

Vaccination to enhance the antitumor activity of GD2 chimeric antigen receptor expression VZV-specific T cells in subjects with advanced sarcomas

Administration of Her2 Chimeric Antigen Receptor Expressing T Cells for subjects with advanced sarcoma (HEROS)

Featured Leukemia Trials and Novel Therapies

AALL15P1: Azacitidine and combination chemotherapy in treating infants with acute lymphoblastic leukemia and KMT2A gene rearrangement

AALL1131: Combination chemotherapy in treating young patients with newly-diagnosed high-risk B acute lymphoblastic leukemia and Ph-like TKI sensitive mutations

AALL1231: Combination chemotherapy with or without Bortezomib in treating younger patients with newly-diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma

AALL1331: Blinatumomab in treating younger patients with relapsed B-cell acute lymphoblastic leukemia

AALL1521: A Phase 2 study of Ruxolitinib with chemotherapy in children with acute lymphoblastic leukemia

AALL1621: Inotuzumab Ozogamicin in treating younger patients with relapsed or refractory CD22 positive B acute lymphoblastic leukemia

AAML1531: Response-based chemotherapy in treating newly-diagnosed acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome

ADVL1411 — A Phase I/II study of BMN673 plus Temozolomide

AflacLL1602 ENCERT

Autologous T-cells expressing a second generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA)

Efficacy and Safety of Daratumumab in Pediatric and Young Adults With Relapsed or Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

T2016-003: Epigenetic Reprogramming in Relapsed/Refractory AML

KYMRIAH®: The first FDA-approved gene therapy for relapsed or refractory B-cell acute lymphoblastic leukemia (ALL)

TACL-CFZ008 - Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

TACL-T2012-002: Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL

TACL-2014-001: A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

Featured Retinoblastoma Trials

Featured Thyroid Cancer Trials

For a complete list of clinical trials offered at Texas Children's Hospital, visit

Over 80% of our patients are involved in a clinical trial or study since research shows that children treated on a clinical trial have better outcomes. Every eligible patient is considered for entry in National Cancer Institute-approved trials, and the vast majority are registered in these studies.  We work closely with referring physicians and families to identify appropriate options for each individual child and to support the child and the whole family through the entire treatment process.

Interested in learning more? Frequently asked questions about clinical trials